Clinical Trials Browser

Graft vs Host Disease × Cytarabine × Other hematologic neoplasm × Clear all

Graft vs Host Disease, Leukemia

NCT00004878 2020-07-31

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00429416 2016-11-29

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Phase 1/2 Completed

14 enrolled 11 charts

Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT02461121 2015-06-04

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Phase 3 Completed

156 enrolled

Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Myeloid, Acute

NCT00002833 2012-07-30

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Phase 2 Completed

53 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Clinical Trials

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia